PHASE II STUDY OF 9-AMINOCAMPTOTHECIN IN CHRONIC LYMPHOCYTIC LEUKEMIA

9-氨基喜树碱治疗慢性淋巴细胞白血病的 II 期研究

• 批准号: 6114315
• 负责人: MICHAEL R GREVER
• 金额: $ 2.06万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114315
• 关键词: brca gene; camptothecin; chronic lymphocytic leukemia; circulating neoplastic cell; clinical research; human subject; human therapy evaluation; molecular oncology; multidrug resistance; neoplasm /cancer chemotherapy; tumor suppressor genes

This study is to evaluate the efficacy and toxicity of 9- aminocamptothecin(9-AC) a topoisomerase I inhibitor, in patients with chronic lymphocytic leukemia. It is also to correlate antitumor activiy of 9-AC with laboratory markers of tumor resistance.

本研究旨在评价9-氟尿嘧啶的疗效和毒性。 拓扑异构酶I抑制剂--氨基喜树碱(9-AC)治疗慢性支气管炎 慢性淋巴细胞白血病。它还与抗肿瘤活性相关 9-AC与肿瘤耐药的实验室标记物。